在Utero Tenofovir暴露可能不会影响婴儿骨骼

StephenW

In Utero Tenofovir Exposure May Not Affect Infant Bones

By Reuters Staff

August 14, 2018


NEW YORK (Reuters Health) - A new pilot study suggests prenatal tenofovir exposure does not have a significant effect on infant bone mineral content (BMC) or bone mineral density (BMD).

Six-month-olds whose mothers were on the antiviral drug showed a trend toward lower BMC and BMD, although the difference was not statistically significant, Dr. Athena P. Kourtis of the Centers for Disease Control and Prevention (CDC) in Atlanta and her colleagues found.

"Our findings are overall reassuring and provide support for the current WHO and NIH recommendations that include TDF in the preferred regimens for HIV-infected and HIV/HBV co-infected pregnant women," they conclude in The Pediatric Infectious Disease Journal, online July 31.

The Tenofovir in Pregnancy study, a phase 2 trial, enrolled 35 pregnant women coinfected with HIV and hepatitis B virus (HBV), below the target sample size of 80. Participants were randomized to tenofovir/lamivudine/lopinavir-ritonavir or zidovudine/lamivudine/lopinavir-ritonavir.

At birth, BMC was 10% lower in tenofovir-exposed infants than in unexposed infants, and 6% lower at six months of age. BMD was 4% lower at birth and 3% lower at six months in the exposed infants compared to the unexposed infants.

The study's small sample size meant it did not have the power to detect statistically significant differences between exposed and unexposed infants, the authors note.

"Notwithstanding the small sample size, recently reported initial findings from larger trials in HIV/HBV co-infected and HBV-monoinfected women seem to confirm our findings," they conclude.

The CDC, the Guanxi Provincial Center for Disease Control and Prevention, and Gilead Sciences, Inc., through a grant to the CDC foundation, funded the study.

Dr. Kourtis was not available for an interview by press time.

SOURCE: https://bit.ly/2vVlkg4

Pediatr Infect Dis J 2018.

StephenW

在Utero Tenofovir暴露可能不会影响婴儿骨骼

路透社工作人员

2018年8月14日


纽约（路透社健康） - 一项新的试验性研究表明，产前替诺福韦暴露对婴儿骨矿物质含量（BMC）或骨矿物质密度（BMD）没有显着影响。

母亲使用抗病毒药物的6个月大的人表现出降低BMC和BMD的趋势，尽管差异无统计学意义，亚特兰大疾病控制和预防中心（CDC）的Athena P. Kourtis博士和她同事发现。

“我们的研究结果总体上令人放心，并为目前世界卫生组织和美国国立卫生研究院的建议提供支持，其中包括TDF在HIV感染和HIV / HBV共感染孕妇的首选治疗方案中，”他们在7月31日在线儿科传染病杂志上总结道。 。

妊娠期替诺福韦研究是一项2期试验，招募了35名合并感染艾滋病毒和乙型肝炎病毒（HBV）的孕妇，目标样本量低于80.参与者随机分为替诺福韦/拉米夫定/洛匹那韦 - 利托那韦或齐多夫定/拉米夫定/洛匹那韦，利托那韦。

出生时，接触替诺福韦婴儿的BMC比未暴露婴儿低10％，六个月时低6％。与未暴露的婴儿相比，暴露婴儿的BMD在出生时降低4％，在6个月时降低3％。

作者指出，该研究的样本量较小，意味着它没有能力检测暴露和未暴露婴儿之间统计学上的显着差异。

“尽管样本量很小，但最近报道的大型HIV / HBV合并感染和HBV单一感染女性试验的初步结果似乎证实了我们的研究结果，”他们总结道。

疾病预防控制中心，关西省疾病预防控制中心和吉利德科学公司通过向疾病预防控制中心基金会提供资助，为该研究提供资金。

Kourtis博士在截稿时没有接受采访。

消息来源：https：//bit.ly/2vVlkg4

Pediatr Infect Dis J 2018。